Pluri (PLUR) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pluri (PLUR) has outperformed TScan Therapeutics (TCRX) over the past year, losing 75.5% versus a loss of 88.5%. Over five years, PLUR leads with a -95.2% price change compared with -96.6% for TCRX. TScan Therapeutics is the larger company by market cap ($15.5 million vs $12.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLUR | TCRX |
|---|---|---|
| Share price | $1.00 | $0.2282 |
| Market cap | $12.61M | $15.47M |
| 1-day change | -3.85% | -17.59% |
| YTD return | -66.56% | -77.18% |
| 1-year return | -75.49% | -88.47% |
| 5-year return | -95.23% | -96.62% |
| EPS (TTM) | $-2.44 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.87 | $2.57 |
| 52-week low | $0.85 | $0.2243 |
| Distance from 52-week high | -79.47% | -91.12% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | +338.21% |
| Average volume | 25.99K | 779.81K |
| Shares outstanding | 12.61M | 63.50M |
| Employees | 92 | 138 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLUR has outperformed TCRX by 13.0 percentage points over the past year.
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Healthcare · Biotechnology · 138 employees
PLUR vs TCRX FAQ
Which is bigger, Pluri or TScan Therapeutics?
TScan Therapeutics (TCRX) is larger, with a market capitalization of $15.47M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, PLUR or TCRX?
PLUR returned -75.49% over the past 12 months, compared with -88.47% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Pluri and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.